AASK Cohort Study

高血压性肾病通常会进展。非裔美国人协会的主要目标 肾脏病和高血压的研究)队列研究是前瞻性地确定肾功能的病程 高血压肾病患者中非裔美国人肾脏疾病进展的危险因素 推荐的抗高血压治疗。第二个目标是确定心血管疾病的发生 并评估其风险因素。 AASK队列研究是一项前瞻性观察性研究，是AASK试验的延伸。AASK 初步检测3种降压药物(雷米普利、美托洛尔)对肾功能的影响 和氨氯地平)和2个水平的血压控制。在1094名试验参与者中，约有650至700人 尚未达到终末期肾病(ESRD)的患者可能会参加队列研究。风险因素 需要研究的变量包括环境、遗传、生理和社会经济变量。主要的肾脏结局是 综合临床结果定义为血肌酐增加一倍，终末期肾病，或死亡。药物治疗 高血压，从血管紧张素转换酶抑制剂雷米普利开始，提供给所有参与者。在这 这项研究直接控制了肾脏疾病进展的两个主要决定因素(治疗 高血压和肾脏保护、抗高血压药物的使用)。队列中随访的最短持续时间 研究为期5年(总计9至12年，包括AASK试验期间)。 归根结底，来自AASK队列研究的数据应该会增强我们对风险因素和 决定肾脏疾病进展的过程。这样的结果可能最终会导致新的战略 延迟或预防ESRD。

Hypertensive kidney disease commonly progresses. The primary objective of the AASK (African American Study of Kidney Disease and Hypertension) Cohort Study is to determine prospectively the course of kidney function and risk factors for kidney disease progression in African-Americans with hypertensive kidney disease who receive recommended antihypertensive therapy. A secondary objective is to determine the occurrence of cardiovascular disease and assess its risk factors. The AASK Cohort Study is a prospective, observational study that is an extension of the AASK trial. The AASK trial tested the effects on kidney function of 3 medications used as initial antihypertensive therapy (ramipril, metoprolol and amlodipine) and 2 levels of blood pressure control. Of the 1,094 trial participants, approximately 650 to 700 individuals who have not reached end stage renal disease (ESRD) will likely enroll in the Cohort Study. Risk factors to be studied include environmental, genetic, physiologic, and socio-economic variables. The primary renal outcome is a composite clinical outcome defined by doubling of serum creatinine, ESRD, or death. Medication treatment for hypertension, beginning with the angiotensin converting enzyme inhibitor ramipril, is offered to all participants. In this fashion, the study directly controls two of the major determinants of kidney disease progression (treatment of hypertension and use of reno-protective, antihypertensive medication). The minimum duration of follow-up in the Cohort Study is 5 years (total of 9 to 12 years, including the period of the AASK trial). Ultimately, data from the AASK Cohort Study should enhance our understanding of the risk factors and processes that determine the progression of kidney disease. Such results might eventually lead to new strategies that delay or prevent ESRD.